Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.83) by 1.45 percent. This is a 27.27 percent decrease over losses of $(0.66) per share from the same period last year.